When I author an opinion piece, I like to keep my followers updated on important changes in the company's fortunes, or to my investment thesis if they occur within a 3-month time frame by expressing thoughts in the comments section of that article. This, however, is not always adequate to the task at hand, and that is now the case where Nektar (NASDAQ:NKTR) is concerned.
I would dearly love to refer you back to that piece, but it's now embargoed for Seeking Alpha Pro readers only. Suffice it to say that Nektar is a burgeoning powerhouse in biotechnology as it morphs from a developmental stage company, into a hybrid, income-generating commercial stage venture.
Crucial to its fortunes,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|